Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
Public ClinicalTrials.gov record NCT02197130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease. A total of approximately 260 subjects are planned to be randomized in the study. Primary endpoint is the change from baseline in the Total Motor Score (TMS) assessment of the Unified Huntington Disease Rating Scale (UHDRS) after 26 weeks of treatment. secondary endpoints will include change from baseline in the Total Maximum Chorea (TMC) score of the UHDRS after 13 and 26 weeks of treatment and Clinical Global Impression-Improvement score after 13 and 26 weeks of treatment.
Study identification
- NCT ID
- NCT02197130
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 272 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2014
- Primary completion
- Aug 31, 2016
- Completion
- Sep 30, 2016
- Last update posted
- Nov 16, 2017
2014 – 2016
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Kirklin Clinic of UAB Hospital | Birmingham | Alabama | 35233 | — |
| The University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| University of California, Irvine | Irvine | California | 92697 | — |
| Ronald Regan UCLA Medical Center Drug Information Center | Los Angeles | California | 90095 | — |
| UCLA Neurology Clinic | Los Angeles | California | 90095 | — |
| UCLA Radiology | Los Angeles | California | 90095 | — |
| Rocky Mountain Movement Disorders Center | Englewood | Colorado | 80113 | — |
| University of Florida Center for Movement Disorders and Neurorestoration | Gainesville | Florida | 32607 | — |
| Indiana University Health Neuroscience Center | Indianapolis | Indiana | 46202 | — |
| Massachusetts General Hospital | Charlestown | Massachusetts | 02129 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Albany Medical College | Albany | New York | 12208 | — |
| Wake Forest Baptist Medical Center - Dept. of Neurology | Winston-Salem | North Carolina | 27157 | — |
| Cleveland Clinic Foundation Hospital Pharmacy | Cleveland | Ohio | 44195 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Davis Medical Center | Columbus | Ohio | 43210 | — |
| The Wexner Medical Center at the Ohio State University | Columbus | Ohio | 43221 | — |
| Wexner Medical Center at the Ohio State University | Columbus | Ohio | 43221 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02197130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2017 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02197130 live on ClinicalTrials.gov.